Each individual cell within a human body acquires a certain number of somatic mutations during a course of its lifetime. These mutations originate from a wide spectra of both endogenous and exogenous mutational processes that leave distinct patterns of mutations, termed mutational signatures, embedded within the genomes of all cells. In recent years, the vast amount of data produced by sequencing of cancer genomes was coupled with novel mathematical models and computational tools to generate the first comprehensive map of mutational signatures in human cancer. Up to date, >30 distinct mutational signatures have been identified, and etiologies have been proposed for many of them. This review provides a brief historical background on examination of mutational patterns in human cancer, summarizes the knowledge accumulated since introducing the concept of mutational signatures and discusses their future potential applications and perspectives within the field.
Introduction
The body of an average adult contains ~40 trillion cells (1) . The DNA of each individual cell is exposed to daily assaults by both exogenous and endogenous sources of DNA damage (2) . These could originate from lifestyle choices (e.g. tobacco smoking or chewing), normal cellular activities (e.g. spontaneous deamination of methylated cytosines), or a failure in DNA replicative or repair machineries (e.g. aberrant function of the mismatch repair pathway) (3) . Unrepaired damage may remain fixed within the genetic code in the form of a mutation (4) . As such, the genome of each cell becomes an involuntary tape that records the activities of both exogenous and endogenous mutational processes operative throughout a person's lifetime (5) . Being able to read and understand these 'mutational records' is essential from a basic biological perspective, as it offers novel means to identify and study unexplored mechanisms of mutagenesis, and from a practical perspective, as it generates knowledge that can be translated into cancer prevention strategies, such as reduction of exposures to newly discovered environmental mutagens.
Our ability to effectively read somatic mutations acquired within the genomes of individual normal cells remains largely restricted by a lack of technology that offers error-free in vitro amplification of DNA content from a single cell (6) . An alternative way to amplify such a low amount of DNA is to exploit the rigorous replicative machinery that resides within a single cell through its in vitro expansion until there is sufficient quantity of DNA generated to study its sequence. Although such experiments have been performed in vitro, for example see ref. (7), many normal cell types cannot be cultured nor expanded from a single cell and the variety of available normal human tissue types remains scarce. Given such limitations, an alternative approach is to study mutations accumulated in cancer genomes since, at a first approximation, cancer arises from a single cell that has acquired an indefinite ability to proliferate autonomously (8, 9) . Examining somatic mutations in human cancer is further enabled by the large amounts of sequencing data from cancer genomes that has been generated and made freely available over the past decade (10).
From a practical perspective, the majority of somatic mutations in a cancer genome are passengers and, as such, are believed to be a by-product of the mutational processes operative throughout the lineage of the cancer cell (5) . In contrast, very few mutations are drivers that, by definition, contribute to clonal expansion. Although an individual cancer genome may have recorded more than a million passenger mutations, it rarely has an excess of 10 driver mutations (5, 8, 9, 11) .
Throughout the past three decades, several different approaches were employed to read the 'mutational records' buried within cancer genomes. These evolved from early studies on mutational patterns in commonly mutated cancer genes (12) (13) (14) to recent development of advanced mathematical approaches to identify mutational signatures across genome-wide sequencing data from thousands of cancer patients (15, 16) . In this review, we provide a brief historical perspective on understanding mutagenesis through examination of mutational patterns and summarize knowledge accumulated from the identification of signatures of mutational processes in human cancer.
Patterns of somatic mutations found in single genes
Early efforts exploring types of mutations found in human cancer focused on examining somatic mutations in single commonly mutated genes, notably TP53 (12) (13) (14) . In these studies, the coding region of TP53 in a cancer sample was sequenced to identify somatic mutations. Such experiments allowed detection of single-base substitutions and (in some cases) small insertions and deletions (i.e. indels). In principle, there are six possible types of single-base substitutions: C > A, C > G, C > T, T > A, T > C and T > G. Note that we report single-base mutations as the pyrimidine of the mutated Watson-Crick base pair, for example a C:G > A:T substitution will be referred to as a C > A substitution.
Usually, no more than one substitution was found in a TP53 gene per cancer sample, and mutations were compiled across multiple samples from the same cancer type (12) (13) (14) . These early studies provided two remarkable examples (17, 18) of mutagen specific mutational patterns: (i) skin cancers associated with history of exposure to ultraviolet light exhibited C > T mutations predominantly occurring at dipyrimidines, a pattern of mutations matching an in vitro exposure of DNA to ultraviolet light (19) and (ii) lung cancers of patients with a history of tobacco smoking exhibited a strong C > A pattern of mutation, matching an in vitro exposure to benzo[a]pyrene, a known tobacco carcinogen (20) . These studies, therefore, elegantly demonstrated that mutational processes leave specific molecular fingerprints on the genomes of cancer cells (21) . It should be noted that the exploration of patterns of TP53 mutations yielded other insights into carcinogenesis and mutagenesis, reviewed in detail in refs. (12) (13) (14) .
Patterns of somatic mutations found in cancer genomes
Examination of patterns of mutations in TP53 provided the first evidence that cellular genomes indeed record the activity of mutational processes. Notably, these analyses offered insights for mainly strong mutagenic activities that generate the majority of mutations in samples from a particular cancer type. For example, surveying patterns of single-base mutations in TP53 of small cell lung carcinomas is extremely informative of the past history of tobacco smoking as exposure to tobacco smoke is strong within lung tissue and causes the majority of mutations found in individual lung cancers. However, within an individual lung cancer, there may have been multiple mutational processes operative, each contributing its own spectra of somatic mutations to the final catalogue of mutations observed in TP53. As such, this final catalogue will contain a mixed record of various past exposures from different mutational processes (Figure 1) . Therefore, although combining mutations from multiple samples may inform on strong individual mutational processes, it generates a jumbled mixture of mutational patterns that are uninformative of the quantity and individual characteristics of other, perhaps weaker, mutational activities (2, 16) . Additionally, the coding region of TP53 is believed to be under selection in most types of cancer, introducing a selection bias within the spectrum of somatic mutations under examination (22) .
Prior to the widespread use of next-generation sequencing, two studies attempted to address some of the hitherto mentioned limitations by performing a capillary sequencing survey of 518 protein kinase genes across multiple samples (23, 24) . These studies confirmed the existence of distinct mutational features in cancer genomes and reported novel patterns of mutations specific for particular cancer types, for example C > T transitions preceded by thymine (i.e. C > T at TpC dinucleotides; mutated base underlined) in breast cancer (23, 24) .
A true explosion of insights, however, came alongside the development of high-throughput next-generation sequencing technologies that allowed rapid and cost-effective examination of exome (i.e. all protein coding regions in the human genome) and even whole-genome sequences derived from cancer patients (25) . Early next-generation sequencing efforts largely confirmed observations made from pioneering studies of mutational patterns within TP53. The cancer genome of a malignant melanoma, cancer of the skin associated with exposure to ultraviolet light, was shown to contain predominately single-base C > T substitutions and CC > TT dinucleotide substitutions both occurring at dipyrimidines (26) . Similarly, the cancer genome of a small cell lung carcinoma was found to be peppered with C > A substitutions (26) consistent with exposure to known tobacco carcinogens (20) .
In the following years, a plethora of individual laboratories, institutes, as well as national and international consortia generated and published vast amounts of cancer genomics data (10, . These data encompassed large numbers of distinct cancer types and allowed detailed and unbiased examination of the patterns of somatic mutations across human cancer (3). Whereas many of these studies did not necessarily focus on exploring or reporting specific mutational characteristics, they provided a detailed molecular characterization of various types of human cancer. In the following paragraph, we will briefly review some of the more tantalizing observations on mutational features reported in the hitherto cited studies.
Larger-scale sequencing studies that included dozens of skin cutaneous melanomas substantiated the previous notion that the genomes of cancers associated with exposure to ultraviolet light display ubiquity of C > T and CC > TT mutations. In contrast, same studies demonstrated that cancer genomes of acral melanomas have an overall lower mutational burden that is dominated by C > T transitions at CpG sites (55 (46, 47) . These studies revealed that lung cancers of smokers carry 10 times as many somatic mutations as lung cancers of non-smokers. In accordance with earlier studies on benzo[a]pyrene exposure (73) , the difference between smokers and non-smokers was mainly due to an increase of C > A transversions, reflecting tobacco-smokeassociated damage (46, 47) . Two independent publications reported high numbers of T > A transversions (mainly at TpG and TpA dinucleotides) within genomes of upper urinary tract (viz. urothelial carcinoma) cancers from patients that have previously taken substances containing aristolochic acid (74, 75) . This was a first association of exposure to aristolochic acid, a group 1 carcinogen according to the International Agency for Research on Cancer, with a very specific mutational spectrum (74, 75) . A separate analysis on the genomes of recurrent cancers post-treatment with temozolomide, an alkylating antineoplastic agent, revealed yet another distinct pattern of somatic mutations described by C > T substitutions predominately occurring at TpC and TpT dinucleotides (76) . Perhaps less surprisingly, larger-scale sequencing surveys of microsatellite unstable colorectal, gastric and uterine cancers associated with mismatch repair deficiencies demonstrated that these cancers exhibit a high overall mutational burden. In addition to previously known high frequency of indels enriched at microsatellite unstable regions, these studies also found that microsatellite unstable cancers have specific features of singlebase substitutions, predominantly composed of C > T transitions and C > A transversions (35, 66, 67) . Interestingly, C > T and C > A substitution pattern was also detected in a subset of microsatellite stable uterine and colorectal cancers, implying a separate mutational process generating these types of substitutions from the one in mismatch repair deficient cancers. The overall mutational burden in such cancers exceeded even the mutational loads of microsatellite unstable tumors designating them the term 'ultra-hypermutators' (35, 67) . The excessive mutational frequency in ultra-hypermutator endometrial cancers was originally associated with mutations in the exonuclease domain of polymerase ε (67). Other notable observations on patterns of mutations in human cancer from next-generation sequencing data include higher than expected numbers of T > G transversions in the immunoglobulin genes of chronic lymphocytic leukemia (33) and the cancer genomes of esophageal adenocarcinomas (37) , as well as a distinct pattern of C > T and C > G mutations at TpC sites in a subset of breast cancers (31) . Overall, the plethora of studies above portrays different palettes of mutational features in distinct cancers, pointing toward variable mutational activities operating in different tissues types.
From patterns of somatic mutations to mutational signatures
Application of next-generation sequencing indeed allowed a rapid read-out of the 'mutational record' of a cancer genome, therefore addressing some of the limitations haunting previous studies of mutational patterns in TP53 (2). However, in addition to being able to read the 'mutational record' encoded within the genome of a cancer cell, one also needs to be able to deconvolute the cocktail of various mutational patterns resulting from the activities of different mutational processes that were operating throughout its cancer cell linage (77) . It was this 'un-mixing' that mandated the development of a new generation of mathematical models and computational tools that can in a meaningful way retrieve the jumbled mutational records residing within the genomes of cancer cells. In early 2013, we published the first mathematical model alongside a freely available computational The pattern of each signature is displayed according to the 96 substitution classification defined by the substitution class and sequence context immediately 3′ and 5′ to the mutated base. The probability bars for the six types of substitutions are displayed in different colors. The mutation types are on the horizontal axes, whereas vertical axes depict the percentage of mutations attributed to a specific mutation type. All mutational signatures are displayed based on the trinucleotide frequency of the human genome. Note that y-axes have been limited to 20% for consistency, even though some mutational signatures have mutation types contributing >20%.
framework to extract signatures of mutational processes from data generated by next-generation sequencing technologies (77). This mathematical model described a signature of a mutational process as a non-negative discreet probability density function and a genome of a cancer as a weighted sum (i.e. composite) of multiple distinct mutational signatures. The sum was weighted by the exposures of the mutational signatures, i.e. the numbers of somatic mutations attributed to different signatures in a cancer genome (Figure 1 ). This simple linear mathematical model of mutational signatures in human cancer essentially described the recording of mutational processes on cancer genomes as a specific subtype of the well-known blind signal separation (BSS) problems (77) .
BSS problems are a specific class of problems examining a set of mixtures from different signals, usually recorded on multiple distinct devices, without any prior knowledge about the underlying mixing of the recorded signals or the characteristics of these signals (78) . Solving a BSS problem is equivalent to unscrambling the original signals by using the data in the recordings. In principle, there are many different approaches for solving a BSS problem and, from a mathematical perspective, most of these are based on minimizing a specific objective cost function that can be constrained in different ways (78) . For example, one can constrain the cost function in such a way that it identifies only signals that are both statically independent from one another as well as sparse as possible (78) . The choice of constraints for a specific problem usually depends on the desired results and prior knowledge of the original problem.
The BSS problem of mutational catalogues generated from cancer genomes was solved by employing a non-negative constraint for both mutational signatures and their exposures (78) . Biologically, this translates into assuming that a mutational process generates somatic mutations that can only accumulate in the genome of a cell and cannot be reversed (78) . To resolve the non-negatively constrained cancer genomics problem, we used the multiplicative update algorithm (79) and provided an open source computational framework for deciphering signatures of mutational processes from cancer genomics data (78) . The framework was extensively evaluated using real and simulated data demonstrating its applicability to both whole-exome and whole-genome sequenced cancer genomes (78) . This framework was subsequently used for developing the first comprehensive map of mutational signatures across the spectrum of human neoplasia (16) . It is worth noting that, recently, additional computational frameworks for identifying mutational signatures have also been published (80) (81) (82) (83) .
Mutational signatures in human cancer
The first targeted examination of mutational signatures in human cancer evaluated whole-genome sequencing data from 21 breast cancers (31) . In order to increase the specificity of mutational signatures, the study extended the original classification of six types of single-base substitutions by including both the base 5′ and the base 3′ to the somatic mutation. Four possible 3′ bases and four possible 5′ bases to the mutated base generate 16 possible trinucleotide combinations for each of the 6 substitution types resulting in a novel classification of a total of 96 substitution types (e.g. one such type is C > A at CCA, mutated based is underlined).
Examining the 21 breast cancer genomes by leveraging this extended classification and the novel computational framework, revealed signatures of multiple distinct mutational processes (31) . Some of these were associated with the activity of known mutational processes, whereas others remain of mysterious origins. Notably, this study was the first to identify two mutational signatures attributed to the aberrant activity of APOBEC family of deaminases in human cancer based on the similarity of the mutation types these enzymes cause when studied in other biological systems (31) . One of the signatures was characterized predominately by C > T mutations at TCN trinucleotides, while the other one generated mostly C > G mutations at TCN sites. Additionally, the examination of 21 breast cancer genomes for the first time demonstrated the existence of a specific base substitution mutational signature associated with the inactivation of BRCA1 or BRCA2, adding to the already known spectra of mutations associated with BRCA deficiencies. Disentangling the mutational signatures from the same set of genomes also allowed timing their activity through the evolution of the cancer in each patient (84) . Whereas traces of some of the mutational processes were detected early in the progression of breast cancer, others became active only in later subclones (84) .
The evaluation of this handful of breast cancers was followed by a large-scale pan-cancer meta-analysis that deciphered signatures of mutational processes operative across 30 different cancer types and derived from >7000 patients (16) . The analysis revealed substitution signatures of >20 distinct mutational processes. Over the following years, the map of mutational signatures was further elaborated by individual studies that examined specific cancer types: breast cancer (12), prostate cancer (85-87), liver cancer (88), renal cancer (89), B-cell lymphoma (90) , several different types of childhood cancers (91), multiple myeloma (92), acute lymphoblastic leukemia (93) and chronic myelomonocytic leukemia (94) . Currently, there are 31 known and validated signatures of mutational processes, named numerically as signature 1 through signature 31. The patterns of these 31 mutational signatures have been derived from analyzing cancer genomics data from >12 000 patients. The patterns of most of these mutational signatures and up to date information about them can be found on the COSMIC website, http://cancer.sanger.ac.uk/ cosmic/signatures. In the next section of this review, we will provide a brief summary of known and speculated etiologies associated with each of the identified mutational signatures. To simplify the accumulated knowledge of mutational signatures, we have separated them into three categories: (i) mutational signatures associated with endogenous mutational processes (Figure 2 ), (ii) mutational signatures associated with exogenous mutational processes ( Figure 3 ) and (iii) signatures of mutational processes with unknown origins (Figure 4 ).
Mutational signatures associated with endogenous mutational processes
There are currently 11 mutational signatures that are believed to be a result of the activity of endogenous mutational processes (Figure 2 ). Although the mutational processes generating these signatures are most likely endogenous to the cell, it is foreseeable that at least some of these endogenous processes could still be affected and triggered by external factors such as inflammation or viral infection.
Mutational signatures 1 and 5 were found in every analyzed cancer type and the majority of examined individual cancer samples (15) . Signature 1 is predominately characterized by C > T mutations occurring at NCG trinucleotides, whereas signature 5 exhibits a rather uniform patter of mutations with small peaks and a strand bias for T > C mutations at ATN trinucleotides. In accordance with these signatures being found in all analyzed cancer types and their quantities being associated with the age of a patient at diagnosis, they likely reflect activities of endogenous processes that generate mutations at a constant rate throughout the lifetime of all cells, even before the onset of cancer (15) . Indeed, the pattern of signature 1 (Figure 2 ) is consistent with spontaneous deamination of 5-methylcytosine, a process known to be active in normal tissues (95) . In contrast, the mutational process underlying signature 5 remains elusive. Additionally, signatures 1 and 5 almost perfectly recapitulate the pattern of de novo germline mutations, further confirming that, even though they were originally found in cancer tissues, these two signatures are operative in the normal germline (96) . The rate of accumulation of these two mutational signatures has been quantified in >30 different tissue types (15) . Their rates vary from almost 100 somatic mutations accumulated in a genome per year in a cell from the kidney, to <2 mutations accumulated in a genome per year in cell from the brain (15) . Due to their ubiquitous nature in normal and cancer tissues, signatures 1 and 5 are believed to have significant implications for human evolution, aging, cancer and potentially other diseases (15, 96, 97) . In addition to these two clock-like mutational signatures, four others have also been associated with endogenous origins: signatures 2, 9, 10 and 13.
Signature 2 is predominately defined by C > T mutations at TCN trinucleotides, whereas signature 13 is mostly dominated by C > A and C > G mutations at TCN trinucleotides (16) . Both mutational signatures have been attributed to the activity of the APOBEC family of deaminases. Based on the types of mutations and their sequence context, it has been speculated that these signatures likely stem from the aberrant activity of APOBEC3A and/or APOBEC3B enzymes (98) (99) (100) . Recent studies have demonstrated that APOBEC mutagenesis occurs on the lagging-strand template during DNA replication (101, 102) and that mutations attributed to these two mutational signatures are enriched in early replicating regions, parts of the genome with high gene density, and regions enriched with active chromatin (103) . Furthermore, APOBEC3A/APOBEC3B germline deletion polymorphism, which effectively places APOBEC3A sequence under 3′ UTR of APOBEC3B and confers elevated risk of breast cancer (104) (105) (106) , has recently been associated with the higher mutational burden attributed to the two signatures of speculated APOBEC origin (107) . In human cancer, signatures 2 and 13 have been observed in approximately half of the examined cancer types and a quarter of the examined cancer samples (15, 16) making them the most prevalent mutational signatures after the ones attributed to endogenous molecular clocks.
Signature 9 exhibits a rather flat mutational profile with some more specific features of T > G mutations. This mutational signature has been found exclusively in B-cell-derived hematologic malignancies, and it has been attributed to the faulty activity of the error-prone polymerase η taking place during somatic hypermutation (16, 33, 108) .
Signature 10 is described predominately by a combination of C > A substitutions at TCT trinucleotides, C > T substitutions at TCG trinucleotides and T > G substitutions at TTT trinucleotides. It has been found in small proportions of colorectal, uterine, cervical and breast cancers and since associated with mutations in the proofreading domain of polymerase ε (notably, Pro286Arg and Val411Leu) (16, 40, 67) .
In addition to the above-mentioned six mutational signatures associated with endogenous mutational processes, another five have been associated with failure of DNA repair mechanisms in the cell: signatures 3, 6, 15, 20 and 26.
Signature 3 exhibits a rather flat mutational profile, and it has been found in cancers of the breast, ovary, pancreas and stomach (16, 109) . Signature 3 has been associated with inactivating mutations in BRCA1 and BRCA2, involved in error-free doublestrand break repair via homologues recombination (16, 109) . Intriguingly, this mutational signature has also been identified in Downloaded from https://academic.oup.com/carcin/article-abstract/37/6/531/1744820 by guest on 30 December 2018 many samples lacking mutations in BRCA1 and BRCA2, indicating that double-strand break repair via homologous recombination may potentially be disabled by the means of BRCA promoter methylation or inactivation of another gene within the pathway (109) . Consistent with this finding, it has been speculated that signature 3 might serve as a better predictor of an inability to repair double-strand break by homologous recombination and as such a useful biomarker for a response to platinum therapy and/ or use of PARP inhibitors (110) .
Signatures 6, 15, 20 and 26 are believed to stem from the loss of DNA mismatch repair activity as they were found in exclusively microsatellite unstable cancers (15, 16) . Signature 6 is predominately described by C > T mutations at NCG and GCN trinucleotides, as well as C > A mutations at CCT trinucleotides. Signature 15 exhibits C > T mutations at GCN trinucleotides, but lacks some of the other features of signature 6, whereas signature 20 not only generates predominately C > A mutations at CCT trinucleotides (as does signature 6) but also contains characteristic T > C mutations at NTG trinucleotides. Signature 26 is described by a relatively uniform pattern of T > C mutations. Some of these four mutational signatures are found in large proportions (>10% of examined samples) of colorectal, uterine and stomach cancers as well as in small proportions (usually <3%) of many other cancer types (15, 16) . The differences in mutational patterns between these four mutational signatures are currently unknown, but they might represent a cumulative outcome of different types and combinations of defects in the mismatch repair machinery.
Mutational signatures associated with exogenous mutational processes
In addition to mutational signatures reflecting the activity of endogenous mutational processes, seven of them ( Figure 3 ) have been up to date associated with exogenous exposures.
Signatures 4, 7, 22, 24 and 29 have all been attributed to environmental mutagens. Signature 4 is characterized by C > A and T > A mutations, exhibiting a strong transcriptional strand bias that indicates a damage on the purine and a potential interplay with a transcription-coupled nucleotide excision repair (16) . It is found only in cancer types with known epidemiological association to tobacco smoking: lung adenocarcinoma, lung squamous, small cell lung carcinoma, esophagus adenocarcinoma, esophagus squamous, hepatocellular carcinoma and cancers of the head and neck (16) . Additionally, signature 4 is enriched within the lung cancer genomes of tobacco smokers when compared with cancer genomes from lungs of lifelong non-smokers (16) .
Signature 7 has been found in cancer types associated with exposure to ultraviolet light, viz., melanoma and lip cancer (16). It is described by C > T and CC > TT mutations at dipyrimidines with a strong transcriptional strand bias, indicating the formation of pyrimidine photodimers repaired by transcription-coupled nucleotide excision repair (16) . Signature 22 is predominately described by T > A substitutions located at NTG and NTA trinucleotides and exhibiting a transcriptional strand bias indicating damage on adenine. This mutational signature has been identified only in cancer samples with known exposures to aristolochic acid, originally, urothelial renal pelvis carcinoma (74, 75) and more recently in bladder and kidney cancers (75, 111, 112) . The origins of the three signatures described above (i.e. signatures 4, 7 and 22) were recently reconfirmed in an experimental study sequencing mouse embryonic fibroblasts exposed to, respectively, benzo[a]pyrene, ultraviolet light and aristolochic acid (20) .
Signatures 24 and 29 both display a C > A substitution pattern with a transcriptional strand bias (15, 88) . The patterns of mutations in these two signatures differ from one another as well as from the C > A pattern of mutation exhibited by signature 4 ( Figure 3 ). Signature 24 has been found only in liver cancers from patients with known exposures to aflatoxin (88) . Signature 29 has been found exclusively in gingivo-buccal oral squamous cell carcinoma of tobacco chewers. The difference in patterns of the mutational signature associated with tobacco smoking (i.e. signature 4) and the one associated with tobacco chewing (i.e. signature 29) is currently unclear but may reflect additional constituents used to lace chewing tobacco and/or the process of combustion, as well as the differences between efficiencies in repair machineries within the corresponding tissue types.
Two mutational signatures from the current panel have been associated with antineoplastic drug treatment: signatures 11 and 31. Both signatures exhibit a transcriptional strand bias. Signature 11 generates predominately C > T mutations located at NTC and NTT trinucleotides, and it has been found in samples treated with alkylating agents (16) . Signature 31 was detected within the genomes of several chronic myelomonocytic leukemias treated with inhibitors of DNA methylation (viz. 5-aza-2′-deoxycytidine) (94) .
Signatures of mutational processes with unknown origins
In addition to those signatures for which there is an existing speculation about their source or association to an underlying mutational processes, 13 Figure 4) .
Two of these signatures have been found across multiple cancer types and reflect the majority of mutational events in at least one cancer type, calling for future studies to unravel their causalities. Signature 17, with a specific pattern of T > G mutations, has been found in six cancer types analyzed up to date and accounts for the majority of mutations in esophageal adenocarcinoma (16, 113) . Signature 18, dominated by C > A mutations, was observed in at least three cancer types and represents a predominant mutational process branding the genomes of neuroblastomas (16) . On the contrary, the vast majority of the unexplained mutational signatures has been identified in a single cancer type or in a limited number of cancer samples. Nevertheless, the entire spectra of known 31 mutational signatures, including the ones that up until today appear to be low in prevalence, has been validated as in ref. (16) and thus reflects traces of genuine mutational activities (15, 16) . Signatures 12 and 16 are found in liver cancer, and these signatures exhibit transcriptional strand bias of T > C substitutions. Signature 14 has been observed in <10 samples of low-grade glioma and uterine carcinoma (16) . Signature 19 has so far been found only in few pilocytic astrocytomas, whereas signature 21 has been identified exclusively in gastric cancer (16) . Signature 23 exhibits strong transcriptional strand bias of C > T mutations, and it has been found in only 2 out of 290 examined liver cancers (16, 88) . Signatures 25 and 27 are both dominated by T > A mutations of different patterns that exhibit a transcriptional strand bias. They have been found, respectively, in cell lines derived from Hodgkin lymphomas and primary tumors of renal clear cell carcinoma (16) . Finally, signature 28 has been observed in stomach cancer, whereas signature 30 has been found only in a handful of breast cancers (16) .
Conclusions and future explorations
In the past 5 years, the introduction of the concept of mutational signatures has significantly advanced our understanding of mutagenesis operative in both normal and cancerous human cells. Examination of thousands of cancer genomes has revealed signatures of >30 mutational processes, many of which still have unknown etiologies. It is foreseeable that some mutational signatures of mysterious etiologies represent consequences of currently unknown lifestyle choices. Understanding their origins may prove instrumental for both providing insights into the disparities of cancer risks across the world as well as for educating the public about potential ways to reduce the risk of getting cancer. Mutational signatures may also find their way into the clinic as a useful marker for failed DNA repair mechanisms that could be useful predictor of a response to different treatments. It has already been speculated that mutational signatures might serve as a strategy to detect cancers sensitive to platinum therapy and/or PARP inhibitors. It is foreseeable that other treatments, such as antibody-targeting programmed cell death-1, might also benefit from the use of mutational signatures as was recently shown for lung cancer patients where genomic landscape shapes the therapy response (114) . Elucidating the sources of unknown mutational signatures could therefore lead into novel avenues for both cancer prevention and cancer treatment.
Exploration of mutational signatures has so far been predominately focused on examining cancer genomes. However, each cell within a human body records activities of a wide spectra of mutational processes operative in its belonging tissue type, throughout the lifetime of an individual. The advancement of single-cell sequencing technologies is therefore expected to provide the means to elucidate tissue-specific mutagenesis operative within individual cells of normal and diseased tissues other than cancer.
